Objective: To evaluate correlations between real-world (RW) improvements in Parkinson’s disease (PD)-related sleep disturbances with foslevodopa/foscarbidopa (LDp/CDp) treatment, daytime sleepiness, and quality of life (QoL).
Background: Disrupted sleep is a frequent nonmotor symptom experienced by patients with advanced PD (aPD), leading to a diminished QoL. The elucidation of associations between RW improvements in sleep disturbances following LDp/CDp treatment and QoL is needed.
Method: ROSSINI (NCT06107426) is an ongoing 3-year, multicountry, prospective, observational study of adults with aPD who are LDp/CDp-naïve. Of the 105 LDp/CDp-naïve patients enrolled ≥6 months, 98 patients in this interim analysis received LDp/CDp infusion and had both baseline and ≥1 postbaseline efficacy assessment. Change from baseline to month 6 (M6) in PD-related sleep disturbances, (Parkinson’s Disease Sleep Scale-2 [PDSS-2]), daytime sleepiness (Epworth Sleepiness Scale [ESS]), and QoL (39-item Parkinson’s Disease Questionnaire [PDQ-39] scores) were evaluated. Spearman correlations assessed associations between sleep scores and QoL at baseline and for change from baseline to M6.
Results: Statistically significant (*P < .05) and clinically meaningful improvements (score reductions) were observed for PDSS-2 (least squares mean difference [SE]: -5.2* [1.4]) and PDQ-39 (-5.6* [1.8]) scores following 6 months of LDp/CDp treatment from baseline in LDp/CDp-naïve patients, whereas ESS scores remained unchanged (-0.9 [0.6], P = .148). Baseline PDSS-2 scores showed a weak positive correlation with baseline PDQ-39 scores [Table 1]. Similarly, baseline ESS and PDQ-39 scores were moderately and positively correlated [Table 1]. No significant correlation was observed between 6-month improvements in PDSS-2 and PDQ-39 scores; 6-month improvements in ESS scores showed a weak positive correlation with 6-month improvements in PDQ-39 scores [Table 1].
Conclusion: PD-related sleep disturbances and daytime sleepiness may be associated with poorer QoL prior to treatment. Improvements in daytime sleepiness following 6 months of LDp/CDp treatment during routine care may contribute to improved QoL in patients with aPD.
Table 1
To cite this abstract in AMA style:
I. Malaty, T. Henriksen, T. Mestre, R. Rodriguez, P. Schwingenschuh, M. Simu, L. Bergmann, S. Caughlin, M. Gopalkrishnan, P. Kukreja, M. O’Meara, J. Carlos Parra, M. Shah, W. Jost. Disrupted Sleep and Daytime Sleepiness are Associated With Poorer Quality of Life in Advanced Parkinson’s Disease: ROSSINI Interim Results [abstract]. Mov Disord. 2026; 41 (suppl 1). https://www.mdsabstracts.org/abstract/disrupted-sleep-and-daytime-sleepiness-are-associated-with-poorer-quality-of-life-in-advanced-parkinsons-disease-rossini-interim-results/. Accessed October 1, 2026.« Back to 2026 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/disrupted-sleep-and-daytime-sleepiness-are-associated-with-poorer-quality-of-life-in-advanced-parkinsons-disease-rossini-interim-results/